查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1465571

卵巢癌诊断市场- 依产品类型（仪器/分析仪、消耗品）、诊断测试（影像[CT、MRI、超音波]、血液检查、活检）、癌症类型（上皮细胞、生殖细胞、基质细胞肿瘤）、最终用途- 2024 - 2032 年全球预测

Ovarian Cancer Diagnostic Market - By Product Type (Instruments/Analyzers, Consumables), Diagnostic Tests (Imaging [CT, MRI, Ultrasound], Blood Test, Biopsy), Cancer Type (Epithelial, Germ Cell, Stromal Cell Tumor), End-use - Global Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 250 Pages | 商品交期: 2-3个工作天内

价格
简介目录

在该领域不断增加的研发力道的推动下，2024 年至 2032 年间，全球卵巢癌诊断市场规模的复合年增长率将达到 6.6%。由于卵巢癌在早期阶段很难被发现，因此迫切需要改进的诊断工具和技术。例如，2024 年 1 月，佐治亚理工学院综合癌症研究中心 (ICRC) 的研究人员将机器学习技术与血液代谢物资料相结合，创建了一种新型测试，能够在研究队列的样本中以93% 的准确率识别卵巢癌。

随着研究人员深入了解与卵巢癌相关的分子机制和生物标记，创新的诊断方法正在出现。这些进步包括液体活检技术、基因组分析和影像方式，提供更准确和及时的疾病检测。因此，医疗保健提供者和患者越来越多地转向这些尖端的诊断解决方案，推动了市场需求，并为改善卵巢癌诊断和治疗结果带来了希望。

整个卵巢癌诊断产业根据产品类型、癌症类型、诊断测试、最终用途和地区进行分类。

从 2024 年到 2032 年，消耗品领域将实现显着的复合年增长率。随着医疗保健提供者优先考虑早期检测和个人化治疗方法，卵巢癌诊断对高品质耗材的需求持续成长。此外，技术升级和创新耗材产品的推出进一步刺激了市场需求，确保医疗保健专业人员能够获得可靠的工具来有效诊断和管理卵巢癌。

从 2024 年到 2032 年，血液检测领域的卵巢癌诊断市场份额将显着增长。 这些检测分析血液中与卵巢癌相关的特定生物标记或遗传特征，提供方便、高效的诊断解决方案。随着医疗保健提供者强调早期检测和个人化治疗策略，对血液诊断测试的需求持续增长。此外，血液检测技术的持续研究和进步进一步推动市场成长，确保透过及时检测和介入来改善患者的治疗结果。

到 2032 年，亚太地区癌症卵巢癌诊断市场将占据可观的市场份额。医疗保健系统正在优先考虑筛检计划和先进诊断技术的使用，以改善患者的治疗结果。因此，对卵巢癌诊断测试（包括影像技术和生物标记检测）的需求持续上升，推动市场成长并促进整个地区医疗保健服务的进步。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 卵巢癌的发生率和盛行率不断上升
      • 提高认识和筛检计划
      • 增加研究和开发活动
      • 卵巢癌诊断的技术进步
    • 产业陷阱与挑战
      • 治疗费用高
      • 严格的监管场景
  • 成长潜力分析
  • 监管环境
  • 技术景观
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 竞争定位矩阵
  • 战略展望矩阵

第 5 章：市场估计与预测：按产品类型，2018 年 - 2032 年

  • 主要趋势
  • 仪器/分析仪
  • 耗材

第 6 章：市场估计与预测：透过诊断测试，2018 - 2032

  • 主要趋势
  • 影像学检查
    • 超音波
    • CT扫描
    • 核磁共振扫描
    • 正子断层扫描
    • 其他影像学检查
  • 验血
    • CA125（癌症抗原 125）
    • HER2（人类表皮生长因子受体2）
    • BRCA（乳癌基因）
    • CEA（癌胚抗原）
    • ER & PR（雌激素受体与黄体素受体）
    • KRAS突变
    • 其他血液检查
  • 活检
  • 其他诊断测试

第 7 章：市场估计与预测：按癌症类型，2018 年 - 2032 年

  • 主要趋势
  • 上皮性肿瘤
  • 生殖细胞肿瘤
  • 间质细胞瘤
  • 其他癌症类型

第 8 章：市场估计与预测：按最终用途，2018 - 2032 年

  • 主要趋势
  • 医院
  • 诊断实验室
  • 诊断影像中心
  • 癌症研究机构
  • 其他最终用户

第 9 章：市场估计与预测：按地区划分，2018 年 - 2032 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 10 章：公司简介

  • Abbott Laboratories
  • Agilent Technologies
  • Canon Medical Systems Corporation
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fujirebio Diagnostics
  • GE HealthCare Technologies Inc.
  • Illumina Inc.
  • Myriad Genetics
  • Philips Healthcare
  • Positron Corporation
  • Qiagen N.V.
  • Quest Diagnostics
  • Siemens Healthineers AG
简介目录
Product Code: 8316

Global Ovarian Cancer Diagnostic Market size will witness a 6.6% CAGR between 2024 and 2032, driven by increasing research and development efforts in the field. With ovarian cancer being notoriously difficult to detect in its early stages, there is a pressing need for improved diagnostic tools and techniques. For instance, in January 2024, researchers at the Georgia Tech Integrated Cancer Research Center (ICRC) integrated machine learning techniques with data on blood metabolites to create a novel test capable of identifying ovarian cancer with 93% accuracy in samples from their study cohort.

As researchers delve deeper into understanding the molecular mechanisms and biomarkers associated with ovarian cancer, innovative diagnostic methods are emerging. These advancements include liquid biopsy techniques, genomic profiling, and imaging modalities, offering more accurate and timely disease detection. As a result, healthcare providers and patients alike are increasingly turning to these cutting-edge diagnostic solutions, driving market demand and fostering hope for improved outcomes in ovarian cancer diagnosis and treatment.

The overall Ovarian Cancer Diagnostic Industry is classified based on the product type, cancer type, diagnostic tests, end-use, and region.

The consumables segment will register a significant CAGR from 2024 to 2032. These essential components, such as test kits, reagents, and disposable instruments, are crucial for conducting diagnostic procedures accurately and efficiently. As healthcare providers prioritize early detection and personalized treatment approaches, the demand for high-quality consumables in ovarian cancer diagnostics continues to grow. Moreover, technological upgrades and the introduction of innovative consumable products further fuel market demand, ensuring that healthcare professionals have access to reliable tools for effective diagnosis and management of ovarian cancer.

The ovarian cancer diagnostic market share from blood test segment will record noteworthy gains from 2024 to 2032. These tests analyze specific biomarkers or genetic signatures in the blood associated with ovarian cancer, offering a convenient and efficient diagnostic solution. As healthcare providers emphasize early detection and personalized treatment strategies, the demand for blood-based diagnostic tests continues to rise. Moreover, ongoing research and advancements in blood test technologies further drive market growth, ensuring improved outcomes for patients through timely detection and intervention.

Asia Pacific cancer ovarian cancer diagnostic market will register a commendable market share through 2032. With a rising prevalence of ovarian cancer and increasing awareness about early detection, there is a growing demand for reliable diagnostic tools in countries across the Asia Pacific. Healthcare systems are prioritizing screening programs and access to advanced diagnostic technologies to improve patient outcomes. As a result, the demand for ovarian cancer diagnostic tests, including imaging techniques and biomarker assays, continues to escalate, driving market growth and fostering advancements in healthcare delivery throughout the region.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast parameters
  • 1.5 Data sources
    • 1.5.1 Primary
    • 1.5.2 Secondary
      • 1.5.2.1 Paid sources
      • 1.5.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising incidence and prevalence of ovarian cancer
      • 3.2.1.2 Growing awareness and screening programs
      • 3.2.1.3 Increasing research and development activities
      • 3.2.1.4 Technological advancements in ovarian cancer diagnostics
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High treatment costs
      • 3.2.2.2 Stringent regulatory scenario
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Porter's analysis
    • 3.6.1 Supplier power
    • 3.6.2 Buyer power
    • 3.6.3 Threat of new entrants
    • 3.6.4 Threat of substitutes
    • 3.6.5 Industry rivalry
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Instruments/analyzers
  • 5.3 Consumables

Chapter 6 Market Estimates and Forecast, By Diagnostic Tests, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Imaging test
    • 6.2.1 Ultrasound
    • 6.2.2 CT scan
    • 6.2.3 MRI scan
    • 6.2.4 PET scan
    • 6.2.5 Other imaging tests
  • 6.3 Blood test
    • 6.3.1 CA125 (Cancer antigen 125)
    • 6.3.2 HER2 (Human epidermal growth factor receptor 2)
    • 6.3.3 BRCA (Breast cancer gene)
    • 6.3.4 CEA (Carcinoembryonic antigen)
    • 6.3.5 ER & PR (Estrogen receptor and progesterone receptor)
    • 6.3.6 KRAS mutation
    • 6.3.7 Other blood tests
  • 6.4 Biopsy
  • 6.5 Other diagnostic tests

Chapter 7 Market Estimates and Forecast, By Cancer Type, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Epithelial tumor
  • 7.3 Germ cell tumor
  • 7.4 Stromal cell tumor
  • 7.5 Other cancer types

Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Diagnostic laboratories
  • 8.4 Diagnostic imaging centers
  • 8.5 Cancer research institutes
  • 8.6 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Italy
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Abbott Laboratories
  • 10.2 Agilent Technologies
  • 10.3 Canon Medical Systems Corporation
  • 10.4 Danaher Corporation
  • 10.5 F. Hoffmann-La Roche Ltd.
  • 10.6 Fujirebio Diagnostics
  • 10.7 GE HealthCare Technologies Inc.
  • 10.8 Illumina Inc.
  • 10.9 Myriad Genetics
  • 10.10 Philips Healthcare
  • 10.11 Positron Corporation
  • 10.12 Qiagen N.V.
  • 10.13 Quest Diagnostics
  • 10.14 Siemens Healthineers AG